Medication info

Rovax 5/80 mg Tablet

Prescription medicationTabletOralExpired
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tabletValsartan›80mg / 1 tablet
Manufacturer / importer
Teragen Etex Co., Ltd.
Appearance
Yellow round film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTP) x 3]
Approval status
Expired

MFDS item code 202006073 · Approved 2020.08.28

This product's status changed to Expired on 2025.08.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension and heart failure; improvement of dyslipidemia; inhibition of cardiovascular risk and atherosclerosis
Who takes it
Adults · Children
Adult dose
This medicine is intended for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, valsartan and rosuvastatin. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be coadministered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is needed. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When coadministered with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily; thereafter, over several weeks, increase the dose according to the patient's tolerability, administering 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with ACE inhibitors is not recommended. 4. Patients with renal impairment: No dose adjustment is needed when creatinine clearance is 10 mL/min or higher. However, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medicine. 5. Patients with hepatic impairment: The daily dose of this medicine should preferably not exceed 80 mg in patients with mild or moderate hepatic impairment. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams once daily. 2. Older adults: No dose adjustment is needed. 3. Patients with renal impairment: No dose adjustment is needed in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination with the same amounts of each active ingredient) for convenience.
Child dose
◆ Valsartan 1. Essential hypertension 6) Children: Safety and efficacy have not been established in children and adolescents under 18 years of age. 3. Reduction of the risk of death after myocardial infarction 6. Children: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Teragen Etex Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure; improvement of dyslipidemia; inhibition of cardiovascular risk and atherosclerosis

  • Essential hypertension
  • heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
View approved original text

This medication is prescribed to patients who require the simultaneous use of valsartan and rosuvastatin. Valsartan is used to reduce the risk of essential hypertension, heart failure, and mortality after myocardial infarction. It is particularly effective in heart failure patients who are intolerant to ACE inhibitors. Rosuvastatin regulates hypercholesterolemia and dyslipidemia, delays the progression of atherosclerosis, and reduces the risk of cardiovascular disease. Additionally, it helps lower the risk of myocardial infarction, stroke, and revascularization procedures. Therefore, this medication is used to improve the health status of patients with hypertension and cardiovascular risks.

How to take

Adult dose

This medicine is intended for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, valsartan and rosuvastatin. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be coadministered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is needed. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When coadministered with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily; thereafter, over several weeks, increase the dose according to the patient's tolerability, administering 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with ACE inhibitors is not recommended. 4. Patients with renal impairment: No dose adjustment is needed when creatinine clearance is 10 mL/min or higher. However, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this medicine. 5. Patients with hepatic impairment: The daily dose of this medicine should preferably not exceed 80 mg in patients with mild or moderate hepatic impairment. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams once daily. 2. Older adults: No dose adjustment is needed. 3. Patients with renal impairment: No dose adjustment is needed in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination with the same amounts of each active ingredient) for convenience.

Child dose

◆ Valsartan 1. Essential hypertension 6) Children: Safety and efficacy have not been established in children and adolescents under 18 years of age. 3. Reduction of the risk of death after myocardial infarction 6. Children: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters; it should be discontinued immediately upon confirmation of pregnancy. It is not safe to use this medication in women who are pregnant or may become pregnant, nursing mothers, patients with severe liver or kidney impairment, and those with muscle disorders. Elderly patients, patients with high potassium levels, patients with slight liver impairment, patients with heart or vascular disease should use this medication carefully, and regular blood tests and kidney function tests may be necessary as required. This medication can cause muscle pain, weakness, and, rarely, rhabdomyolysis (muscle destruction); if symptoms of muscle pain or weakness occur, the healthcare provider should be notified immediately. Furthermore, this medication may affect liver function, so if symptoms of liver dysfunction occur, it should be discontinued and a doctor consulted. There may be interactions with other medications, so if other medications are being taken, be sure to inform a doctor or pharmacist. In the case of overdose, there is no specific antidote, so immediate hospitalization for appropriate treatment is necessary, and appropriate measures are needed if blood pressure becomes excessively low. This medication is not recommended for use in children as safety and effectiveness have not been established. During treatment, driving or operating machinery may cause dizziness, so care should be taken. Lastly, this medication should be kept out of reach of children and not transferred to other containers for safety.

Side effects

dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, weakness, chest pain, facial edema, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased serum liver aminotransferase (AST, ALT) levels, increased serum creatine phosphokinase, increased serum potassium, increased gamma-glutamyl transferase, musculoskeletal stiffness, limb pain, sensory disturbance, anxiety, upper respiratory tract infection, pharyngitis, tonsillitis, spinal stenosis, aphasia, oral hemorrhage, vomiting, insulin-dependent diabetes mellitus, diabetic complications, leg fracture, spinal fracture, fracture, skin mass, second-degree atrioventricular block, vestibular neuritis, retinal detachment, nonspecific skin tumor-like condition, herpes zoster, intervertebral disc herniation, hemoptysis, sputum disease, bronchitis, sensory abnormalities, hoarseness, gastroesophageal reflux, diverticulitis, gastritis, stomatitis, carpal tunnel syndrome, chills, facial flushing, increased blood sugar, increased triglycerides, elevated blood pressure, worsening hypertension, neck/shoulder pain, toe fracture, osteomyelitis, skin infection, nonspecific dermatitis, localized skin reaction, palpitations, worsening angina, auditory disturbances, hyperactive bladder, increased serum creatinine, vitreous detachment, reproductive dysfunction (male), prostatic hyperplasia, laceration, anemia, tinnitus, tension increase, decreased motor function, confusion, rash, myalgia, vascular edema, hypersensitivity reaction, diabetes, headache, dizziness, constipation, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia and systemic symptoms associated drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorder, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, myasthenia gravis, ocular myasthenia, hypotension, altered consciousness, circulatory collapse, shock, tachycardia, bradycardia, orthostatic dizziness, orthostatic hypotension, renal dysfunction, hyperkalemia, angioedema, syncope, vasculitis, interstitial pneumonia, hypoglycemia, vascular edema, hepatitis, renal failure, shock, syncope, loss of consciousness, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, decreased red blood cell volume, decreased hemoglobin, viral infection, upper respiratory tract infection, cough, diarrhea, fatigue, rhinitis, sinusitis, abdominal cramps, abdominal pain, arthralgia, drowsiness, atrial fibrillation, thirst, anorexia, lethargy, serum sickness, epistaxis, hepatitis, arrhythmia, elevated liver function test results, increased serum creatinine concentration, increased BUN, elevated CK, myalgia, myopathy, increased transaminases, increased blood sugar, increased triglycerides, elevated blood pressure, worsening hypertension, palpitations, auditory disturbances, increased serum creatinine, retinal detachment, herpes zoster, intervertebral disc herniation, laceration, dyspepsia, anemia, tinnitus, tension increase, decreased motor function, confusion, chest pain, rash, myalgia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to light, so it should be stored in a tightly sealed container that prevents light exposure. It is advisable to maintain a storage temperature between 1 degree and 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Yellow round film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTP) x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.